How Context of Use and Fit for Purpose Validation Shape Biomarker Success – A CRO’s Perspective on Building Smarter Biomarker Strategies
Every drug development program is built around a series of scientific questions.
Has the drug reached its target? Is it producing the intended biological effect? Is the biological system responding? Is there enough evidence to justify continued investment? Ultimately, will patients benefit?
The answers to these questions don’t come from a single assay or even a single biomarker. They come from selecting the right biomarker at the right stage of development.
Yet biomarker strategy is often approached as though all biomarkers serve the same purpose. In reality, every biomarker is designed to answer a different scientific question. Understanding those distinctions is critical for designing efficient studies, reducing development risk, and generating evidence that supports confident decision-making.
From a contract research organization (CRO) perspective, the most successful biomarker strategies don’t begin with selecting an assay. They begin by defining the scientific question that needs to be answered. Once that objective is clear, the appropriate biomarker, analytical platform, and validation strategy can be selected to generate meaningful, actionable data. This is commonly referred to as Context of Use (CoU) and Fit for Purpose (FfP), respectively.
Biomarkers Are More Than Measurements. They Are Decision-Making Tools
A biomarker is often defined as a measurable characteristic that indicates a biological process or response to a therapeutic intervention. While technically accurate, that definition doesn’t fully capture their role in drug development.
Biomarkers are evidence. They reduce uncertainty by helping sponsors answer the critical questions that determine whether a program advances, changes direction, or stops altogether. As therapies move from discovery through clinical development, the questions evolve. Early in development, researchers need to confirm that a drug is interacting with its intended target. Later, they need to understand whether that interaction changes biology, produces meaningful pharmacologic activity, and ultimately improves patient outcomes. Because those questions are fundamentally different, the biomarkers used to answer them are different as well.
Matching the Biomarker to the Scientific Question
Rather than thinking about biomarkers as a list of categories, it is often more useful to think about the questions they answer throughout development.
Did the Drug Reach Its Target?
The first question is often the simplest, yet one of the most important. Target engagement biomarkers provide evidence that a therapeutic successfully binds or interacts with its intended target. They answer a foundational question: Did the drug get where it was supposed to go? These biomarkers provide confidence that the therapeutic has reached its biological target, but they do not demonstrate whether that interaction produces a functional effect.
Did Target Engagement Change Biology?
Proof of Mechanism (PoM) biomarkers determine whether engaging the target changes biological activity as intended. They measure functional consequences at or near the target, providing evidence that the therapeutic mechanism is working as designed. For sponsors, this represents an important transition from demonstrating interaction to demonstrating biological activity.
Is the Biological System Responding?
Proof of Pharmacology (PoP) biomarkers examine downstream responses across pathways and physiological systems. Cytokine changes, pathway activation, gene expression, and metabolite shifts all help demonstrate whether the therapeutic is producing broader pharmacologic effects. These biomarkers often support dose selection, PK/PD modeling, and translational decision-making by connecting molecular activity to measurable biological responses.
Is There Enough Evidence to Continue Development?
As programs mature, biomarker data become part of a much larger decision-making framework. Proof of Concept (PoC) is often misunderstood as a biomarker category, when it is more accurately viewed as a development milestone supported by multiple lines of evidence. Biomarker results are integrated with pharmacokinetic, pharmacodynamic, exposure-response, and early efficacy data to determine whether a therapeutic demonstrates sufficient promise to advance. At this stage, biomarkers help inform one of the most important questions in development: Should this program move forward?
Is the Therapy Delivering Meaningful Benefit?
Proof of Efficacy (PoE) biomarkers provide evidence that biological activity leads to meaningful improvements in disease outcomes. Whether evaluating tumor response, disease activity scores, functional assessments, or validated clinical endpoints, these biomarkers help demonstrate that a therapeutic is providing benefit where it matters most: the patient.
Table: Biomarkers Across the Stages of Drug Development
Biomarkers Can Also Be Classified by Their Role
The previous framework focuses on when biomarkers contribute during development. Another useful perspective is why they are being used.
Some biomarkers help identify the patients most likely to respond to therapy. Others monitor disease progression, detect safety signals, support regulatory endpoints, or help stratify patient populations for clinical trials. Understanding these functional roles allows sponsors to design studies that answer multiple scientific questions simultaneously while generating more robust evidence.
Predictive Biomarkers
Predictive biomarkers identify patients who are more likely to respond to a specific therapeutic intervention. They are foundational to precision medicine and are frequently incorporated into patient enrichment strategies and companion diagnostic development.
Safety Biomarkers
Safety biomarkers provide early evidence of toxicity or adverse biological responses before clinical symptoms appear. By monitoring biological indicators of risk, sponsors can make informed decisions regarding dose escalation, patient monitoring, and overall study safety.
Monitoring Biomarkers
Monitoring biomarkers evaluate changes over time. They help investigators assess disease progression, therapeutic response, or long-term treatment effects throughout a study.
Surrogate Endpoint Biomarkers
In situations where traditional clinical endpoints may require years to observe, surrogate endpoint biomarkers can provide earlier evidence of therapeutic benefit when appropriately validated. These biomarkers often play an important role in regulatory decision-making and clinical trial design.
Patient Stratification Biomarkers
Not every patient responds to therapy in the same way. Stratification biomarkers help define patient populations based on biological characteristics, allowing sponsors to improve enrollment strategies, reduce variability, and better understand treatment response across different subgroups.
Table: Biomarker Roles and Categories
Why Biomarker Strategy Matters
Selecting a biomarker is only one part of the process. Sponsors must also determine whether the biomarker is capable of answering the scientific question being asked, whether the analytical method is appropriate for the intended use (CoU), and whether the resulting data will support future development and regulatory objectives (FfP).
These considerations influence everything from assay selection and fit-for-purpose validation to sample collection, study design, and data interpretation. A well-designed biomarker strategy generates evidence that informs decisions. A poorly aligned strategy can produce large volumes of data without providing the clarity needed to move a program forward.
The CRO Perspective: Turning Questions into Evidence
An experienced bioanalytical CRO contributes far more than analytical testing.
Successful biomarker programs require an understanding of drug development, assay performance, regulatory expectations, and the scientific context surrounding each measurement. That perspective helps ensure biomarker strategies are aligned with study objectives from the earliest stages of development.
Whether supporting target engagement studies, fit-for-purpose assay validation, multiplex biomarker analysis, flow cytometry, ligand binding assays, molecular assays, or LC-MS/MS, the objective remains the same: generating high-quality evidence that supports confident scientific and development decisions.
The most valuable biomarker programs don’t measure everything that can be measured. They measure what matters most.
Building Better Biomarker Strategies Starts with Better Questions
Biomarkers are fundamental to modern drug development because they provide the evidence needed to understand biology, evaluate therapeutic activity, and support informed decisions.
But no biomarker exists in isolation. Each one is selected to answer a specific scientific question (CoU), and those questions evolve throughout the development journey.
By aligning biomarker selection with study objectives and development milestones, sponsors can generate more meaningful data, reduce uncertainty, and make better-informed decisions at every stage of drug development.
At KCAS Bio, we believe biomarker strategy begins long before samples enter the laboratory. It begins with understanding the science behind the questions our clients are trying to answer and partnering with them to generate the evidence that moves promising therapies forward.
Frequently Asked Questions
What makes an effective biomarker strategy?
An effective biomarker strategy connects each biomarker to a specific scientific or development question. It considers the stage of development, mechanism of action, analytical technology, validation requirements (FfP), and intended use of the data (CoU). The result is a strategy that reduces uncertainty, strengthens study design, and provides meaningful evidence to guide drug development.
How should biomarker strategy evolve throughout drug development?
Biomarker strategy should evolve as the scientific questions change. Early-stage studies focus on understanding target biology and mechanism of action, while later-stage development emphasizes clinical response, patient stratification, safety, and efficacy. Aligning biomarker selection with each development milestone helps sponsors generate evidence that supports informed decision-making at every stage.
Can one biomarker serve multiple purposes?
Yes. Depending on the study objectives, a single biomarker may support multiple roles. For example, a biomarker may demonstrate pharmacological activity while also monitoring disease progression or helping identify patients most likely to benefit from treatment.
How do I choose the right biomarker for my study?
The best biomarker is the one that answers your study’s primary scientific question. Factors to consider include the stage of drug development, mechanism of action, therapeutic modality, patient population, regulatory expectations, and the analytical performance required to generate meaningful data.
What role does a bioanalytical CRO play in biomarker strategy beyond laboratory testing?
An experienced bioanalytical CRO contributes scientific expertise throughout biomarker planning, assay development, validation, and data interpretation. By helping align biomarkers with study objectives, analytical technologies, and regulatory expectations, CROs help sponsors generate evidence that supports critical development decisions rather than simply producing analytical results.
To learn more about how we can support your biomarker studies, fill out the form below to speak with a scientist.